Last Price
4.12
Today's Change
-0.17 (3.96%)
Day's Change
3.99 - 4.33
Trading Volume
356,125
Market Cap
337 Million
Shares Outstanding
81 Million
Avg Volume
750,191
Avg Price (50 Days)
3.86
Avg Price (200 Days)
4.00
PE Ratio
-2.31
EPS
-1.78
Earnings Announcement
11-Nov-2024
Previous Close
4.29
Open
4.29
Day's Range
3.99 - 4.335
Year Range
2.01 - 6.13
Trading Volume
356,125
1 Day Change
-3.96%
5 Day Change
-8.44%
1 Month Change
29.97%
3 Month Change
11.05%
6 Month Change
-14.17%
Ytd Change
-9.85%
1 Year Change
-9.25%
3 Year Change
-80.46%
5 Year Change
-56.40%
10 Year Change
-72.89%
Max Change
-72.89%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.